Kuhnil first reveals Phase III clinical trial for Omega-3 & Rosuvastatin combination drug
Kuhnil(CEO Young-Joong Kim) announced the Phase III clinical trial result for ‘Rosumega SC,’ a dyslipidemia combination drug, was published in the SCI-level international journal ‘Clinical Therapeutics’ on 6 December.
The paper, generally managed by Circulatory Internal Medicine Professor Hyo-So...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.